Futurist
Photonics, Space, AI Infrastructure & Robotics Commentary
Genomics is quietly coming back to life. Moderna's personalized cancer vaccine with Merck succeeded in a Phase 3 melanoma trial, sending Moderna up almost 100% in a day. The ecosystem spans sequencing (Illumina, PacBio, Thermo Fisher, Agilent), gene editing (CRISPR, Intellia, Beam, Prime), gene therapy (uniQure), tools (Twist, Danaher, Qiagen, Bio-Techne, 10x), diagnostics (Natera, Guardant) and therapeutics (Lilly, Regeneron, Vertex, Moderna, BioNTech, BioMarin, Roche). x.comÂ
Genomics could follow AI's playbook, where ChatGPT drew the attention but NVIDIA was the biggest winner. The winners may not be drug companies but those building the infrastructure behind precision medicine: DNA sequencing (Illumina, PacBio, Thermo Fisher, Agilent), gene editing (CRISPR Therapeutics, Intellia, Beam, Prime Medicine), gene therapy (uniQure), tools (Twist, Danaher, Qiagen, Bio-Techne, 10x Genomics) and diagnostics (Natera, Guardant), alongside Tempus, Recursion and AbCellera. x.comÂ
Moderna's mRNA vaccine news and Twist Bioscience's partnership with Anthropic could spark the cancer and genomics theme across treatments, diagnostics and tools, lifting Personalis, Guardant Health, Twist, HTFL, NeoGenomics and genomics stocks broadly. x.comÂ
Personalis could be a swing trade on breakthrough cancer vaccine news, a holy grail whose importance is hard to overstate. Downstream players in mRNA cancer vaccines may have some juice. x.com x.comÂ
Moderna's vaccine looks weak even in melanoma, the easiest indication for cancer vaccines, casting doubt on harder indications. The reportedly leaked data showed only a 12% difference. Even if approved, it will never get used or sold. x.com x.com x.comÂ
Moderna's cancer-cure mystery and optimism are the conditions that drive big stock moves. Its theme is now hot to trade, alongside related stocks. CoreWeave's 2025 AI data-center IPO rode similar uncertainty about AI revenue while AI was hot; it now faces AI-spending worries. x.comÂ
Tempus AI's latest news is good, even if that sounds crazy. x.comÂ
BioNTech's personalized cancer vaccines look commercially unpromising because a vaccine after a cure draws little interest. Its previous attempts failed after it bought two companies. Melanoma is an easier test that can mislead investors: cancer-vaccine efforts in other indications have repeatedly failed, and this approach is no different. x.com x.com x.comÂ
AI labs will need advanced gene editing to address many of the diseases they pursue, making Prime Medicine's strategic importance hard to overstate as they expand into biology. Cystic fibrosis is a sizable indication; demonstrating the technique works there could open larger indications. x.com x.com x.comÂ
Moderna should be a $500 stock on the strength of its personalized mRNA cancer therapy, now in a Phase 3 trial for the first time. As described in a post shared on the news, the therapy gives the immune system the tumor's genetic fingerprint so T-cells can be trained to find the cancer, while Keytruda removes the brakes cancer places on those T-cells. x.comÂ
Moderna's cash burn and persistent operating losses make profitable commercialization the central constraint despite promising melanoma results. Its revenue remains too small and uneven to cover development costs, while rising diluted shares weaken financial resilience. x.comÂ
Tempus AI's Moderna and Merck collaboration puts its oncology data and algorithms to work on cancer vaccines and immuno-oncology drugs, supporting the commercial value of its pharma data platform. The multiyear agreement adds to its licensing case; Q2 revenue rose more than 21.6% to $382 million, and the EPS loss of $0.04 beat the expected $0.20 loss. Sustained profitability remains prospective. Tempus AI could reach $145. x.comÂ
